# Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease

> **NCT01427322** · EARLY_PHASE1 · TERMINATED · sponsor: **Virginia Commonwealth University** · enrollment: 6 (actual)

## Conditions studied

- Epithelial Cancer

## Interventions

- **DRUG:** Lapatinib
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT01427322
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09
- **Primary completion:** 2014-12
- **Final completion:** 2015-07
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2015-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01427322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01427322, "Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01427322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*